MSOS ETF Inflows Surge as MSO Uplisting Speculation Intensifies

MSOS Capital Inflows Accelerate in Q2 2026

The AdvisorShares MSOS ETF has seen accelerated inflows through May and early June, driven by positioning ahead of potential MSO uplisting catalysts. Dan Ahrens, portfolio manager for the fund, said the capital flows reflect institutional and retail anticipation that one or more large MSOs could file for Nasdaq or NYSE listing within the next 12 months.

MSOS holds positions in Curaleaf, Trulieve, Green Thumb Industries, Verano, and other top-tier MSOs. Inflows typically track sentiment around federal reform timelines and MSO profitability milestones.

Ahrens said the current wave differs from prior speculative runs. Balance sheets are cleaner. EBITDA margins are stable. The math for uplisting is tightening.

Uplisting Speculation Centers on Three Operators

Market chatter has narrowed to three MSOs most likely to pursue major-exchange listing first: Curaleaf, Green Thumb Industries, and Trulieve. All three meet or are close to meeting Nasdaq's quantitative thresholds for market cap, shareholder equity, and cash flow.

• Curaleaf operates in 17 states with trailing-twelve-month revenue above $1.3 billion.
• Green Thumb Industries posted Q1 2026 EBITDA margins near 30%, among the sector's highest.
• Trulieve dominates Florida and has restructured debt to improve its balance sheet ahead of federal reform.

Federal cannabis prohibition remains the primary barrier. Uplisting requires either SAFE Banking passage, full descheduling, or a waiver from exchange regulators permitting plant-touching operators.

Federal Reform Timelines Drive Positioning

Investor positioning reflects two potential federal catalysts: SAFE Banking legislation in the Senate and DEA rescheduling finalization. Ahrens said the cleanest read on current inflows is that capital is betting on a 2026 or early 2027 federal breakthrough, not immediate uplisting.

SAFE Banking has cleared the House twice but stalled in the Senate. A revised version is circulating with bipartisan co-sponsors. DEA rescheduling from Schedule I to Schedule III remains in public-comment review, with a final rule expected no earlier than Q4 2026.

Neither catalyst guarantees uplisting. Schedule III reclassification doesn't remove federal prohibition. SAFE Banking enables banking access but doesn't greenlight major-exchange listings without additional regulatory clarity.

Psychedelics Exposure Adds Complexity to ETF Strategy

Ahrens also discussed AdvisorShares' exposure to psychedelics companies, a small but growing allocation within the fund's portfolio. MSOS holds positions in companies developing psilocybin and MDMA therapies, betting on FDA approval pathways parallel to cannabis reform.

Psychedelics represent less than 5% of the fund's assets under management. The allocation targets companies with Phase 2 or Phase 3 clinical trials underway, not speculative early-stage ventures.

The FDA granted Breakthrough Therapy designation to two psilocybin programs in 2023 and 2024. Approval timelines for MDMA-assisted therapy could arrive as early as 2027, ahead of federal cannabis descheduling.

MSO Fundamentals Improve Ahead of Potential Listings

MSO operating fundamentals have strengthened significantly since 2023, improving the investment case for uplisting-focused capital. Sector-wide EBITDA margins averaged 27% in Q1 2026, up from 22% in Q1 2024, according to data from MSO earnings reports.

Debt restructuring has been aggressive. Curaleaf refinanced $575 million in senior notes in March 2026. Trulieve retired $120 million in convertible debt in April. Green Thumb carries one of the sector's lowest debt-to-EBITDA ratios at 1.8x.

Revenue growth has moderated but stabilized. The top five MSOs posted combined Q1 2026 revenue of $1.9 billion, flat year-over-year but up 4% sequentially. Adult-use markets in New York, Ohio, and Maryland are offsetting saturation in Illinois and California.

What Investors Are Watching Next

Three signals will drive the next wave of MSOS inflows or outflows: Senate movement on SAFE Banking, DEA rescheduling finalization, and any MSO filing activity with Nasdaq or NYSE. Ahrens said the market is pricing in a 40-50% probability of at least one MSO uplisting by mid-2027.

For background on MSO uplisting mechanics and regulatory requirements, see the CannIntel topic hub on MSO uplisting to major exchanges.

The next scheduled Senate Banking Committee hearing on cannabis legislation is June 18. The DEA's public-comment window on rescheduling closes July 22, with a final rule expected three to six months later.